Amphastar enters into $59m settlement with Sandoz and Momenta
20-06-2019
AbbVie secures another Humira settlement
12-10-2018
03-01-2020
Pavel Kapysh / Shutterstock.com
California-based Adamas Pharmaceuticals has entered into a settlement agreement with Novartis’ generics unit Sandoz over a treatment for dyskinesia, the involuntary movements in Parkinson’s disease patients.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Adamas Pharmaceuticals, Novartis, Sandoz, generics, ANDA, settlement, patent infringement, Gocovri, Parkinson’s